New Board Member at Egenix, Inc.

MILLBROOK, N.Y., Feb. 13, 2014 /PRNewswire/ -- Donald Fresne, President and CEO of Egenix, Inc. is pleased to announce the appointment of Dendy Young to its Board of Directors. Dendy Young is the Managing Partner of McLean Capital, LLC, a private equity firm, based in McLean, VA, which focuses on investments in government information technology as well as other angel investments.  He is a member of Blu Venture Investors, a venture capital investment company that supports early stage companies in the Washington DC area. From January 1996 to 2006, Mr. Young was CEO of GTSI Corp. (NASDAQ: GTSI), an enterprise services and solutions provider. Prior to GTSI, Mr. Young served as Chief Executive Officer of Falcon Microsystems, Inc., the second of two privately held, Federally-focus IT companies he founded, and Falcon Systems, Inc. Mr. Young serves on the Executive Committee of the Northern Virginia Technology Council (NVTC), where he holds the position of Chairman of the NVTC TechPAC (Political Action Committee), and on the Boards of the AFCEA Educational Foundation and the Washington Airports Task Force.  He is Chairman of the Board of Navanti Group, LLC, which specializes in risk assessment and the use of social media in countering violent extremism, Qlarion, Inc., which provides expertise in business intelligence, Icaros, which delivers GIS solutions to government and industry, and Personalized Cancer Therapy (Perthera), a company that provides oncologists with personalized recommendations for their patients.  In addition, Mr. Young is on the boards of Omnilink Systems, Inc. a location-based-services company, Core2, which mines big data from the Internet, and Internet Broadcasting Corporation (Vibble), which streams foreign television channels to the US. Mr. Young holds a S.B. in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology and an M.B.A. from the Harvard Business School.

Egenix is a privately held, New York-based biotechnology company focused on the development of innovative cancer therapeutics. The company's therapeutic platform technology consists of small molecule drugs applicable for the treatment and prevention of a broad spectrum of cancers, autism, and Alzheimer's. Our lead drug candidates inhibit the "translation initiation factor" eIF4E, specifically blocking production of multiple cancer promoting proteins and promoting apoptosis (programmed cell death) and upregulation of tumor suppressor genes. The company licensed this technology from Harvard Medical School in 2007. eIF4E is an attractive cancer therapeutic target because every function necessary for cancer growth and metastasis is influenced or mediated be a gene product that is regulated by this translation initiation factor. Data from human cancer xenograft studies using two of our lead compounds tested against breast cancer and melanoma demonstrated 100% tumor inhibition and 20% to 30% tumor reduction. For more information visit www.egenixinc.com

SOURCE Egenix, Inc.